Filter Results:
(1,144)
Show Results For
- All HBS Web
(1,144)
- People (1)
- News (319)
- Research (698)
- Events (5)
- Multimedia (14)
- Faculty Publications (410)
Show Results For
- All HBS Web
(1,144)
- People (1)
- News (319)
- Research (698)
- Events (5)
- Multimedia (14)
- Faculty Publications (410)
- Research Summary
What Makes the Bonding Stick? A Natural Experiment Involving the U.S. Supreme Court and Cross-Listed Firms
On March 29, 2010, the U.S. Supreme Court signaled its intention to geographically limit the reach of the U.S.securities antifraud regime and thus differentially exclude U.S.-listed foreign firms from the ambit of formal U.S.antifraud enforcement. We exploit this... View Details
- August 2023 (Revised May 2024)
- Case
Dicerna Pharmaceuticals: Decision Making in Clinical Trial Design and Operations
By: Satish Tadikonda and Amanda McEwen
The success or failure of Dicerna Pharmaceuticals (Dicerna) as an emerging pharmaceutical company would likely hinge on its lead drug candidate Nedosiran and the company’s ability to see it successfully through clinical development. Ralf Rosskamp, Chief Medical... View Details
Keywords: Business Strategy; Health Testing and Trials; Product Development; Governing Rules, Regulations, and Reforms; Pharmaceutical Industry
Tadikonda, Satish, and Amanda McEwen. "Dicerna Pharmaceuticals: Decision Making in Clinical Trial Design and Operations." Harvard Business School Case 824-018, August 2023. (Revised May 2024.)
- 18 Feb 2016
- News
Challenge Aims to Speed Drug Trials Process
The HBS Health Care Initiative is seeking innovative ideas from the science, patient, business, and medical communities on how to transform trials for precision medicine. Through the HBS Precision View Details
- 31 Oct 2018
- News
Dialysis Giant DaVita Defends Itself In Court And At The Polls
- Web
Statement on Supreme Court Decision | About
Statement on Supreme Court Decision Harvard University leadership, including Dean Srikant Datar, address the Harvard community after the Supreme Court delivered its decision in Students for Fair Admissions... View Details
- 28 Jan 2016
- News
Harvard Business School Launches Precision Trials Challenge
- 2013
- Working Paper
What Makes the Bonding Stick? A Natural Experiment Involving the U.S. Supreme Court and Cross-Listed Firms
By: Amir N. Licht, Christopher Poliquin, Jordan I. Siegel and Xi Li
On March 29, 2010, the U.S. Supreme Court signaled its intention to geographically limit the reach of the U.S. securities antifraud regime and thus differentially exclude U.S.-listed foreign firms from the ambit of formal U.S. antifraud enforcement. We use this legal... View Details
Keywords: Crime and Corruption; International Finance; Investment; Corporate Governance; Governing Rules, Regulations, and Reforms; Courts and Trials; Legal Liability; United States
Licht, Amir N., Christopher Poliquin, Jordan I. Siegel, and Xi Li. "What Makes the Bonding Stick? A Natural Experiment Involving the U.S. Supreme Court and Cross-Listed Firms." Harvard Business School Working Paper, No. 11-072, January 2011. (Revised August 2013.)
- fall 2002
- Article
Science and Medicine in Court: Expert Testimony in the German Thalidomide Trial
By: Arthur A. Daemmrich
Daemmrich, Arthur A. "Science and Medicine in Court: Expert Testimony in the German Thalidomide Trial." Chemical Heritage, no. 20 (fall 2002): 12–13, 28–33.
- 12 Dec 2022
- Research & Ideas
Buy-In from Black Patients Suffers When Drug Trials Don’t Include Them
Black patients and their doctors may be more open to new medications if drug trials included more Black people, new research shows. Currently, Black Americans represent just 5 percent of drug View Details
- 2021
- Chapter
History on Trial: Mau Mau Reparations and the High Court of Justice
By: Jaqueline Bhabha, Caroline M. Elkins and Margareta Matache
Bhabha, Jaqueline, Caroline M. Elkins, and Margareta Matache. "History on Trial: Mau Mau Reparations and the High Court of Justice." In Time for Reparations: A Global Perspective, edited by Jaqueline Bhabha, Margareta Matache, and Caroline M. Elkins, 101–118. Philadelphia, PA: University of Pennsylvania Press, 2021.
- January 2018
- Article
The Central and Unacknowledged Role of the U.S. Food and Drug Administration in the Design and Execution of Medical Device Pivotal Trials
By: Aaron V. Kaplan and Ariel D. Stern
The introduction of new medical devices has transformed cardiovascular care in recent decades. Devices, such as heart valves, pacemakers, stents, ventricular assist devices, and implantable defibrillators, have prolonged and improved the quality of life for millions of... View Details
Keywords: Health Testing and Trials; Business and Government Relations; Governing Rules, Regulations, and Reforms; Information Publishing; Medical Devices and Supplies Industry; United States
Kaplan, Aaron V., and Ariel D. Stern. "The Central and Unacknowledged Role of the U.S. Food and Drug Administration in the Design and Execution of Medical Device Pivotal Trials." JAMA Cardiology 3, no. 1 (January 2018): 5–6.
- 03 Jul 2012
- Research & Ideas
HBS Faculty on Supreme Court Health Care Ruling
The Supreme Court has spoken, and its ruling last Friday has evoked myriad responses from across the United States—from the far right to the far left, from small businesses to giant corporations, from... View Details
- December 1994
- Case
Alpha-Beta Technology, Inc. (B): Trials with Betafectin
This case follows the development of a firm's first product, the public presentation of research results, and the stock market reactions. In spite of successful research, the stock price falls dramatically. Asks why this happened, how concerned the CEO should be,... View Details
Teisberg, Elizabeth O., and Sharon L. Rossi. "Alpha-Beta Technology, Inc. (B): Trials with Betafectin." Harvard Business School Case 795-045, December 1994.
- 17 Sep 2021
- Research & Ideas
The Trial of Elizabeth Holmes: Visionary, Criminal, or Both?
Former Theranos employees began testifying this week against Elizabeth Holmes, the once-celebrated biotech’s founder and CEO, in a criminal trial that has Silicon Valley worried. In opening statements last... View Details
- August 1997 (Revised July 1999)
- Case
Hewlett-Packard's Santa Rosa Systems Division (A): The Trials and Tribulations of a Legacy
By: Michael Beer
Describes the process of transforming a recently formed division of Hewlett-Packard. View Details
Beer, Michael. "Hewlett-Packard's Santa Rosa Systems Division (A): The Trials and Tribulations of a Legacy." Harvard Business School Case 498-011, August 1997. (Revised July 1999.)
- Article
Quantifying the Use of Connected Digital Products in Clinical Research
By: Caroline Marra, Jacqueline L. Chen, Andrea Coravos and Ariel D. Stern
Over recent years, the adoption of connected technologies has grown dramatically, with potential for improving health care delivery, research, and patient experience. Yet, little has been documented about the prevalence and use of connected digital products (e.g.,... View Details
Keywords: Connected Digital Products; Clinical Trials; Health Testing and Trials; Information Technology; Research
Marra, Caroline, Jacqueline L. Chen, Andrea Coravos, and Ariel D. Stern. "Quantifying the Use of Connected Digital Products in Clinical Research." Art. 50. npj Digital Medicine 3 (2020).
- 1984
- Book
The Results and Interpretation of Three Field Trials of Lysine Fortification of Cereals
By: James E. Austin, Jean Pierre Habicht, Max Milner, Vernon Young and Linda D. Myers
Austin, James E., Jean Pierre Habicht, Max Milner, Vernon Young, and Linda D. Myers. The Results and Interpretation of Three Field Trials of Lysine Fortification of Cereals. Washington, D.C.: National Academy Press, 1984.